Peptide Antibiotics Market By Product Type (Glycopeptides, Lipopeptides, Polymyxins, Cyclic Peptides, Polypeptides, Bacteriocins, Other Peptide Antibiotics); By Application (Hospital-Acquired Infections, Skin and Soft Tissue Infections, Bloodstream Infections, Gastrointestinal Infections, Respiratory Infections, Wound and Topical Infections, Food Preservation Applications); By End User (Hospitals and Clinics, Outpatient Infusion Centers, Retail Pharmacies, Pharmaceutical Companies, Research Institutes, Food Processing Companies); By Route of Administration (Injectable, Oral, Topical, Inhaled, Localized Delivery Systems); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Peptide Antibiotics Market: Resistance Pressure Sustains Hospital Demand While Engineered Peptides Address the Approval Gap

The Global Peptide Antibiotics Market was valued at USD 5.13 billion in 2025 and is projected to reach USD 7.36 billion by 2032, expanding at a CAGR of 5.3%, according to Strategic Market Research.

 

The peptide antibiotics market combines established hospital medicines, topical anti-infective products, food-preservation peptides, and an emerging pipeline of synthetic antimicrobial candidates. Commercial demand is concentrated around vancomycin, daptomycin, colistin, polymyxin B, bacitracin, dalbavancin, oritavancin, and nisin, while the scientific discovery pool is several orders of magnitude larger.

 

The Antimicrobial Peptide Database recorded 6,309 peptides as of January 1, 2026, including 3,379 natural antimicrobial peptides, 2,290 synthetic peptides, and 373 experimentally verified predicted peptides, many identified through artificial intelligence-supported screening. Natural peptides included 430 bacterial bacteriocins, 272 plant-derived peptides, and 2,628 animal-derived peptides. At the APD6 publication cut-off in March 2025, the database contained 5,188 entries, including 3,306 natural, 1,380 synthetic, and 239 predicted peptides, showing how quickly synthetic and computational discovery is expanding.

 

Antibacterial activity remains the largest commercial target, although many peptides also show antifungal, antiviral, antibiofilm, wound-healing, anti-inflammatory, or anticancer activity. Fewer than 30 antimicrobial peptides had received FDA or European Medicines Agency approval by October 2024, and approximately 65% of those approved products were cyclic molecules. The gap between more than 6,300 catalogued peptides and fewer than 30 approved antimicrobial products explains why market growth depends more on clinical translation than discovery volume.

 

Artificial intelligence is increasing the number of potential sequences entering early screening, but it does not remove the need for toxicity, stability, serum-activity, and animal-efficacy testing. APD6 noted that AI discovery is progressing from basic activity prediction toward models that must also account for pH, salt, serum effects, resistance, and hemolysis. Validated biological data and development-ready peptide libraries therefore carry more commercial value than unfiltered sequence volume.

 

Antimicrobial Resistance Protects Demand for Reserve Peptide Drugs

Bacterial antimicrobial resistance is the strongest demand driver for peptide antibiotics. The World Health Organization estimates that bacterial AMR was associated with more than 4.7 million deaths worldwide in 2021. Approximately one in six laboratory-confirmed bacterial infections was resistant to antibiotic treatment in 2023, while resistance increased in more than 40% of the pathogen-antibiotic combinations monitored between 2018 and 2023. The average annual increase across those combinations ranged from 5% to 15%.

The commercial consequences extend beyond mortality. WHO projects that treating resistant bacterial infections could cost health systems USD 412 billion annually through 2035, with an additional USD 443 billion in annual productivity losses. Reserve peptide antibiotics gain importance because hospitals must retain treatment options for infections that no longer respond to first-line or second-line drugs. Their use is tightly controlled, so revenue is supported by medical necessity, intravenous administration, treatment complexity, and limited alternatives rather than high prescription frequency.

Regional resistance differences also influence demand. WHO estimates that one in three reported bacterial infections in South-East Asia and the Eastern Mediterranean was resistant in 2023. These regions carry substantial unmet need, although restricted diagnostic capacity, affordability constraints, and uneven access to intensive care limit the use of premium peptide therapies.

Stewardship policies shape the product mix. Access-group antibiotics represented only 53% of global human antibiotic consumption in 2022, while higher-resistance-risk Watch antibiotics accounted for approximately 45% and exceeded 70% of consumption in nearly one-third of countries. The 2030 global target is for at least 70% of antibiotic use to come from the Access group, increasing pressure to reserve peptide antibiotics for confirmed resistant infections.

 

Glycopeptides and Lipopeptides Anchor the Clinical Market

Glycopeptides provide the market’s largest established clinical base. Intravenous vancomycin remains central to the treatment of serious Gram-positive infections involving methicillin-resistant Staphylococcus aureus, bloodstream infections, endocarditis, bone infections, and complicated skin infections. Oral vancomycin serves a separate gastrointestinal market because it acts locally against Clostridioides difficile rather than relying on systemic absorption.

The U.S. burden illustrates the depth of hospital demand. The CDC’s national threat assessment estimated 323,700 MRSA cases and 10,600 deaths among hospitalized patients in 2017. Vancomycin-resistant enterococci caused an estimated 54,500 infections and 5,400 deaths in hospitalized patients during the same reference year. These figures support recurring demand for vancomycin, daptomycin, and newer lipoglycopeptides, although stewardship and resistance monitoring restrict routine use.

Daptomycin occupies a high-value lipopeptide position in complicated skin infections, MRSA bloodstream infections, and right-sided infective endocarditis. It cannot be used for bacterial pneumonia because pulmonary surfactant inhibits its activity. This limitation concentrates demand in hospitals, infectious-disease services, and outpatient infusion programs rather than the broader respiratory antibiotic market.

Polymyxin B and colistin serve difficult Gram-negative infections involving carbapenem-resistant Acinetobacter, Pseudomonas, and Enterobacterales. In the United States, the CDC estimated approximately 12,700 CRE infections and more than 1,100 related deaths in 2020. CRE incidence increased 18% from 2019 to 2023, while infections involving New Delhi metallo-beta-lactamase-producing CRE increased 461%. These trends preserve demand for last-line agents, even though kidney toxicity and emerging colistin resistance restrict broader use.

 

Long-Acting Products and Generic Entry Reshape Hospital Economics

Long-acting lipoglycopeptides such as dalbavancin and oritavancin create value by reducing the number of intravenous administrations required for selected acute bacterial skin and skin-structure infections. Fewer visits can support outpatient treatment, earlier hospital discharge, and lower infusion-related resource use. Their commercial model is therefore linked to total treatment cost rather than drug acquisition price alone.

Generic competition is entering this higher-value category. On October 23, 2025, the FDA approved Teva’s dalbavancin hydrochloride injection as the first generic equivalent of Dalvance for adult and pediatric acute bacterial skin and skin-structure infections. The approval can improve formulary access while shifting competition toward price, sterile manufacturing capacity, supply consistency, and hospital contracts.

Hospital purchasing remains the principal revenue channel. The American Hospital Association reported 6,100 U.S. hospitals, 907,216 staffed beds, and 35.7 million hospital admissions in its 2026 statistics. This infrastructure supports recurring demand for intravenous glycopeptides, lipopeptides, microbiology testing, therapeutic monitoring, and pharmacy inventory. Outpatient infusion centers extend the addressable channel for long-acting products, while retail pharmacies remain more important for oral vancomycin and topical peptide antibiotics.

 

Delivery, Toxicity, and Manufacturing Limit Commercial Conversion

The central market bottleneck is the conversion of laboratory activity into a safe, deliverable medicine. Natural peptides may be degraded by enzymes, cleared rapidly from circulation, bound by plasma proteins, or prevented from reaching infected tissue. Some compounds damage human cells at concentrations close to those needed to kill bacteria. These limitations explain why many clinically used peptide antibiotics are cyclic, locally administered, or delivered intravenously.

Oral systemic delivery remains especially difficult because digestive enzymes break peptide structures down and intestinal absorption is poor. Oral vancomycin is commercially successful because it is intended to remain inside the gastrointestinal tract. Peptides designed for bloodstream exposure generally require intravenous, inhaled, topical, or localized administration.

Manufacturing also affects commercial viability. Short synthetic peptides may be produced chemically, while longer or structurally complex peptides may require recombinant or fermentation-based production. APD6 found that synthetic peptides averaged approximately 19 amino acids, compared with more than 48 amino acids for recombinantly produced peptides. Developers must balance activity, stability, yield, purification cost, scale-up, and reproducibility before a promising sequence can become a regulated product.

These constraints are directing investment toward cyclization, lipid attachment, peptide stapling, nanoparticle delivery, inhaled formulations, controlled-release wound products, and infection-site targeting. A formulation that improves half-life or reduces toxicity can create greater commercial value than discovering another peptide with similar laboratory activity.

 

Pipeline Activity Remains Active but Commercially Fragile

The antibacterial pipeline remains too small for the scale of the resistance problem. WHO reported that the number of antibacterials in clinical development fell from 97 in 2023 to 90 in 2025. The 2025 pipeline included 50 traditional antibacterial agents and 40 non-traditional approaches. Only 15 of the 90 candidates qualified as innovative, and only five were active against at least one WHO critical-priority bacterium. Since July 2017, 17 antibacterial agents targeting priority pathogens had obtained marketing authorization, but only two represented a new chemical class.

The preclinical base is broader but financially fragile. WHO identified 232 preclinical programs across 148 development groups, with 90% of participating companies employing fewer than 50 people. This structure creates dependence on grants, partnerships, licensing, and public funding because small biotechnology companies often lack the capital required for full clinical development and commercialization.

CARB-X funding for Lytica Therapeutics shows how public support is being used to address peptide-specific barriers. The organization awarded up to USD 5.3 million for stapled antimicrobial peptides and offered another USD 11.6 million tied to development milestones, creating potential total support of USD 16.9 million. The program targets resistant Gram-negative infections and explores intravenous and inhaled delivery for lung, urinary tract, and intra-abdominal infections.

Pipeline developers are increasingly focusing on narrower opportunities where local delivery, rapid diagnostics, or pathogen-specific activity can produce a clear clinical advantage. These include infected burns, diabetic wounds, catheter-associated infections, biofilms, fungal nail disease, resistant lung infections, and oral pathogens.

 

Topical, Dental, and Food Applications Broaden the Revenue Base

Topical peptide antibiotics generate broad unit demand through first-aid ointments, eye preparations, wound-care products, and combination formulations. Bacitracin and polymyxin B remain established ingredients because local application avoids many systemic delivery barriers. However, safety concerns and generic competition limit pricing power. A North American Contact Dermatitis Group analysis covering 2001–2018 found that bacitracin accounted for 29.1% of recorded reactions to the topical medication allergens examined, nearly equal to neomycin at 29.4%.

Localized delivery also creates development opportunities. The cyclic antifungal peptide NP213 produced no detectable fungi in nail cultures for 43.3% of patients after 180 days in one Phase IIa study and negative dermatophyte cultures in 56.5% after 360 days in another. C16G2 has reached Phase II evaluation as a targeted peptide intended to reduce Streptococcus mutans, a major bacterial contributor to dental caries, while preserving more of the surrounding oral microbiome.

Nisin provides the largest established non-pharmaceutical peptide antibiotic application. It is produced by lactic acid bacteria and used to suppress selected Gram-positive foodborne organisms. Peer-reviewed literature reports that nisin is approved for food use in more than 50 countries and received U.S. GRAS recognition in 1988. Commercial demand spans dairy products, canned foods, processed meats, sauces, and other formulations where food safety and shelf-life protection influence purchasing.

 

Market Segmentation Reflects Route, Acuity, and End-User Economics

By product class, glycopeptides lead because vancomycin supports large hospital and gastrointestinal treatment volumes. Lipopeptides form a smaller but high-value segment led by daptomycin, while polymyxins retain a strategically important position against resistant Gram-negative infections. Polypeptides and bacteriocins support topical care and food preservation. Fewer than 30 FDA- or EMA-approved antimicrobial peptides, compared with 6,309 catalogued candidates, keep market revenue concentrated around a limited group of mature products.

By route of administration, injectable products account for the greatest pharmaceutical value because severe resistant infections are managed in hospitals. Topical products generate wider unit volumes but face lower prices, retailer competition, and safety scrutiny. Oral demand is concentrated in locally acting gastrointestinal products, while inhaled and targeted-delivery candidates remain pipeline opportunities.

By end user, hospitals lead because they manage bloodstream infections, endocarditis, resistant pathogens, intensive-care cases, renal monitoring, and intravenous treatment. The U.S. hospital network includes 5,121 community hospitals and 775,297 staffed community-hospital beds, creating a large institutional purchasing base. Retail pharmacies dominate topical formulations, while outpatient infusion centers benefit from long-acting glycopeptides.

 

Regional Growth Depends on Access and Reimbursement Innovation

North America leads commercialization through its 6,100-hospital network, established infectious-disease infrastructure, generic manufacturing base, and access to outpatient infusion. Mature products face price erosion, but hospital demand remains supported by MRSA, VRE, CRE, and other resistant infections.

Europe combines substantial demand with tighter stewardship and alternative payment approaches. NHS England’s antimicrobial subscription model separates payment from prescription volume. Products can qualify for annual value bands of GBP 5 million, GBP 10 million, GBP 15 million, or GBP 20 million, depending on clinical value and innovation scores. This model seeks to support revenue without encouraging excessive prescribing.

Asia-Pacific and other emerging regions carry a large resistance burden, with one in three reported infections resistant in parts of South-East Asia and the Eastern Mediterranean. Growth is constrained by diagnostic access, affordability, fragmented procurement, and limited availability of premium reserve drugs. Lower-cost generics, local production, and improved microbiology capacity will determine how much unmet clinical need becomes commercial demand.

 

Competition Moves Toward Portfolio Scale and Hospital Reach

Competition includes generic manufacturers of vancomycin, daptomycin, bacitracin, colistin, and polymyxin B; specialty companies commercializing long-acting lipoglycopeptides; food-ingredient suppliers producing nisin; and biotechnology firms advancing engineered peptides.

CorMedix’s acquisition of Melinta Therapeutics demonstrates the importance of hospital portfolio scale. CorMedix paid USD 300 million upfront and added seven marketed products, including ORBACTIV and KIMYRSA. Melinta’s portfolio generated USD 120 million in 2024 and was expected to deliver USD 125 million to USD 135 million in 2025. The combined company projected USD 35 million to USD 45 million in annual run-rate synergies.

The market outlook will remain selective rather than volume-driven. Established glycopeptides and lipopeptides will generate most near-term pharmaceutical revenue, while generic entry shifts value toward manufacturing reliability, ready-to-administer formats, hospital contracting, and secure supply. Engineered peptides can create the next growth phase if they improve toxicity, stability, biofilm penetration, lung delivery, or activity against resistant Gram-negative bacteria. The scientific base already exceeds 6,300 documented peptides, but commercial success will be determined by the much smaller number that can cross clinical, manufacturing, regulatory, stewardship, and reimbursement barriers.

 

Peptide Antibiotics Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026–2032
Market Size Value in 2025	USD 5.13 Billion
Revenue Forecast in 2032	USD 7.36 Billion
Overall Growth Rate	CAGR of 5.3% (2026–2032)
Base Year for Estimation	2025
Historical Data	2019–2024
Unit	USD Billion, CAGR (2026–2032)
Segmentation	By Product Type, By Application, By End User, By Route of Administration, By Region
By Product Type	Glycopeptides, Lipopeptides, Polymyxins, Cyclic Peptides, Polypeptides, Bacteriocins, Other Peptide Antibiotics
By Application	Hospital-Acquired Infections, Skin and Soft Tissue Infections, Bloodstream Infections, Gastrointestinal Infections, Respiratory Infections, Wound and Topical Infections, Food Preservation Applications
By End User	Hospitals and Clinics, Outpatient Infusion Centers, Retail Pharmacies, Pharmaceutical Companies, Research Institutes, Food Processing Companies
By Route of Administration	Injectable, Oral, Topical, Inhaled, Localized Delivery Systems
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising antimicrobial resistance, increasing hospital-acquired infections, growing demand for reserve antibiotics, expansion of infectious disease surveillance, development of engineered antimicrobial peptides, and adoption of targeted peptide delivery technologies
Customization Option	Available upon request